Genetic polymorphism of CYP2U1, a cytochrome P450 involved in fatty acids hydroxylation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 83, Issue 2, 2010, Pages 105-110

  Devos, Aurore ^a   Lino Cardenas, Christian Lacks ^a   Glowacki, François ^a,b   Engels, Anne ^a   Lo Guidice, Jean Marc ^a   Chevalier, Dany ^a   Allorge, Delphine ^a   Broly, Franck ^a   Cauffiez, Christelle ^a  

^a France Institut Pasteur de Lille   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Arachidonic acid; CYP2U1; Genetic polymorphism; SNP

Indexed keywords

ADENOSINE; CYTIDINE; CYTOCHROME P450; CYTOCHROME P450 2U1; FATTY ACID; GUANOSINE; THYMIDINE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; FATTY ACID METABOLISM; FRANCE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; HYDROXYLATION; INTRON; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 77955419553     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.06.005     Document Type: Article

References (31)

1. Nebert D.W., Russell D.W. Clinical importance of the cytochrome P450. Lancet 2002, 360:1155-1162.
2. Nelson D.R., Koymans L., Kamataki T., et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6:1-42.
3. Ding X., Kaminsky L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003, 43:149-173.
4. Chuang S.S., Helvig C., Taimi M., et al. CYP2U1, a novel human thymus-and brain-specific cytochrome P450, catalyzes ω- and (ω-1)-hydroxylation of fatty acids. J. Biol. Chem. 2004, 279:6305-6314.
5. Karlgren M., Backlund M., Johansson I., Oscarson M., Ingelman-Sundberg M. Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. Arch. Biochem. Biophys. 2004, 315:679-685.
6. Nelson D.R., Zeldin D.C., Hoffman S., Maltais L.J., Wain H.M., Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004, 14:1-18.
7. Karlgren M., Shin-ichi M., Ingelman-Sundberg M. Novel extrahepatic cytochrome P450s. Toxicol. Appl. Pharmacol. 2005, 207:S57-S61.
8. Bièche I., Narjoz C., Asselah T., et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 2007, 17:731-742.
9. Leclerc J., Tournel G., Courcot-Ngoubo Ngangue E., et al. JM profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancers. Biochimie 2010, 92:292-306.
10. Gebremedhin D., Lange A.R., Lowry T.F., et al. Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ. Res. 2000, 87:60-65.
11. Miyata N., Roman R.J. Role of 20-hydroxyeicosatetraenoïc acid (20-HETE) in vascular system. J. Smooth Muscle Res. 2005, 41:175-193.
12. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 2002, 82:131-185.
13. Guengerich F.P. Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Dev. Res. 2000, 49:4-16.
14. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002, 181-182:447-452.
15. Guengerich F.P., Wu Z.L., Bartleson C.J. Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 2005, 338:465-469.
16. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 2005, 207:52-56.
17. Cauffiez C. What have we learned from the novel human cytochromes P450 hidden in the databases?. Curr. Genomics 2006, 7:273-282.
18. Hao C.M., Breyer M.D. Physiologic and pathophysiologic role of lipids mediators in the kidney?. Kidney Int. 2007, 71:1105-1115.
19. Chaudhary K.R., Batchu S.N., Seubert J.M. Cytochrome P450 enzymes and the heart. IUBMB Life 2009, 61:954-960.
20. Powell P.K., Wolf I., Jin R., Laskel J.M. Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 1998, 285:1327-1336.
21. Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem. 2000, 275:4118-4126.
22. Gainer J.V., Bellamine A., Dawson E.P., et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005, 111:63-69.
23. Mayer B., Lieb W., Gotz A., et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005, 46:766-771.
24. Cauffiez C., Klinzig F., Rat E., et al. Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. Biochem. Pharmacol. 2004, 67:2231-2238.
25. Tournel G., Cauffiez C., Billaut-Laden I., et al. Molecular analysis of the CYP2F1 gene: identification of a frequent non-functional allelic variant. Mutat. Res. 2007, 617:79-89.
26. Garat A., Cauffiez C., Hamdan-Khalil R., et al. IMPDH2 genetic polymorphism: a promoter single-nucleotide polymorphism disrupts a cyclic adenosine monophosphate responsive element. Genet. Test. Mol. Biomarkers 2009, 13:841-847.
27. Orita M., Iwahana H., Kanazawa H., Hayashi K., Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. 1989, 86:2766-2770.
28. Hayashi K., Wandell D.W. How sensitive is PCR-SSCP?. Human Mutat. 1993, 5:73-79.
29. Kumarakulasingham M., Rooney P.H., Dundas S.R., et al. Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res. 2005, 11:3758-3765.
30. Downie D., McFadyen M.C., Rooney P.H., et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 2005, 15:7369-7375.
31. Marez D., Legrand M., Sabbagh N., et al. Genetic polymorphism of the human cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997, 7:193-202.